Leflunomide and rheumatoid arthritis: A systematic review of effectiveness, safety and cost implications

Journal of Clinical Pharmacy and Therapeutics

Volumn 25, Issue 4, 2000, Pages 295-302

  Hewitson, ^a   DeBroe, ^a   McBride, ^a   Milne, ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Leflunomide; Rheumatoid arthritis; Systematic review

Indexed keywords

C REACTIVE PROTEIN; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE;

ALLERGIC REACTION; ALOPECIA; ARTICLE; CLINICAL TRIAL; COST UTILITY ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; META ANALYSIS; NAUSEA; PRURITUS; QUALITY OF LIFE; RASH; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME; VERTIGO; WEIGHT REDUCTION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; HUMANS; ISOXAZOLES; PAIN; TREATMENT OUTCOME;

EID: 0033802451     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2000.00296.x     Document Type: Article

References (31)

1. Epidemiology of rheumatoid arthritis: Update
2. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis
3. What is the natural history of rheumatoid arthritis?
4. Mortality in the rheumatic diseases
5. The burden of rheumatoid arthritis: Facts and figures
6. The costs of rheumatoid arthritis
7. The costs of rheumatoid arthritis: Absolute, incremental and marginal estimates
8. The cost of rheumatoid arthritis
9. Science, medicine and the future: Treatment of rheumatoid arthritis
10. Rheumatoid arthritis and its treatment
11. Disease-modifying antirheumatic drugs
12. Second-line drug therapy for rheumatoid arthritis
13. Early arthritis therapy: Rationale and current approach
14. Disease-modifying anti-rheumatic drugs
15. Aggressive treatment of early rheumatoid arthritis to prevent joint damage
16. New drugs in clinical development: Leflunomide
17. Mechanism of action of leflunomide in rheumatoid arthritis
18. Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporine, and levamisole) in patients with rheumatoid arthritis
19. Safety and effectiveness in the treatment of patients with rheumatoid arthritis: Results of a randomized, placebo controlled, phase II study
20. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
21. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
22. Function and health-related quality of life
23. Rapid and responsive health technology assessment: The development and evaluation process in the South and West region of England
24. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
25. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis
26. When is it the 'right' time to initiate an assessment of a health technology
27. Outstanding issues in use of disease-modifying agents in rheumatoid arthritis